Record Information |
---|
Version | 5.0 |
---|
Status | Detected and Quantified |
---|
Creation Date | 2005-11-16 15:48:42 UTC |
---|
Update Date | 2023-02-21 17:15:41 UTC |
---|
HMDB ID | HMDB0001429 |
---|
Secondary Accession Numbers | - HMDB0000973
- HMDB0002105
- HMDB0002142
- HMDB0005947
- HMDB00973
- HMDB01429
- HMDB02105
- HMDB02142
- HMDB05947
|
---|
Metabolite Identification |
---|
Common Name | Phosphate |
---|
Description | Phosphate is a salt of phosphoric acid and is an essential component of life. Organic phosphates are important in biochemistry, biogeochemistry, and ecology. In biological systems, phosphorus is found as a free phosphate ion in solution and is called inorganic phosphate, to distinguish it from phosphates bound in various phosphate esters. Inorganic phosphate is generally denoted Pi and at physiological (neutral) pH primarily consists of a mixture of HPO2-4 and H2PO-4 ions. Phosphates are most commonly found in the form of adenosine phosphates (AMP, ADP, and ATP) and in DNA and RNA, and can be released by the hydrolysis of ATP or ADP. Similar reactions exist for the other nucleoside diphosphates and triphosphates. Phosphoanhydride bonds in ADP and ATP, or other nucleoside diphosphates and triphosphates, contain high amounts of energy which give them their vital role in all living organisms. Phosphate must be actively transported into cells against its electrochemical gradient. In vertebrates, two unrelated families of Na+-dependent Pi transporters carry out this task. Remarkably, the two families transport different Pi species: whereas type II Na+/Pi cotransporters (SCL34) prefer divalent HPO4(2), type III Na+/Pi cotransporters (SLC20) transport monovalent H2PO4. The SCL34 family comprises both electrogenic and electroneutral members that are expressed in various epithelia and other polarized cells. Through regulated activity in apical membranes of the gut and kidney, they maintain body Pi homeostasis, and in salivary and mammary glands, liver, and testes they play a role in modulating the Pi content of luminal fluids. Phosphate levels in the blood play an important role in hormone signalling and in bone homeostasis. In classical endocrine regulation, low serum phosphate induces the renal production of the secosteroid hormone 1,25-dihydroxyvitamin D3 (1,25(OH)2D3). This active metabolite of vitamin D acts to restore circulating mineral (i.e. phosphate and calcium) levels by increasing absorption in the intestine, reabsorption in the kidney, and mobilization of calcium and phosphate from bone. Thus, chronic renal failure is associated with hyperparathyroidism, which in turn contributes to osteomalacia (softening of the bones). Another complication of chronic renal failure is hyperphosphatemia (low levels of phosphate in the blood). Hyperphosphatemia (excess levels of phosphate in the blood) is a prevalent condition in kidney dialysis patients and is associated with increased risk of mortality. Hypophosphatemia (hungry bone syndrome) has been associated with postoperative electrolyte aberrations and after parathyroidectomy (PMID: 17581921 , 11169009 , 11039261 , 9159312 , 17625581 ). Fibroblast growth factor 23 (FGF-23) has recently been recognized as a key mediator of phosphate homeostasis and its most notable effect is the promotion of phosphate excretion. FGF-23 was discovered to be involved in diseases such as autosomal dominant hypophosphatemic rickets, X-linked hypophosphatemia, and tumour-induced osteomalacia in which phosphate wasting was coupled to inappropriately low levels of 1,25(OH)2D3. FGF-23 is regulated by dietary phosphate in humans. In particular, it was found that phosphate restriction decreased FGF-23, and phosphate loading increased FGF-23. In agriculture, phosphate refers to one of the three primary plant nutrients, and it is a component of fertilizers. In ecological terms, because of its important role in biological systems, phosphate is a highly sought after resource. Consequently, it is often a limiting reagent in environments, and its availability may govern the rate of growth of organisms. Addition of high levels of phosphate to environments and to micro-environments in which it is typically rare can have significant ecological consequences. In the context of pollution, phosphates are a principal component of total dissolved solids, a major indicator of water quality. Dihydrogen phosphate is an inorganic salt used in numerous analytical methods, and in buffer solutions (PMID: 15369738 ). It is one of several forms of the phosphate ion that can exist physiologically. It readily forms salts with sodium or potassium cations. |
---|
Structure | InChI=1S/H3O4P/c1-5(2,3)4/h(H3,1,2,3,4) |
---|
Synonyms | Value | Source |
---|
[PO(OH)3] | ChEBI | Acide phosphorique | ChEBI | Acidum phosphoricum | ChEBI | H3PO4 | ChEBI | Orthophosphoric acid | ChEBI | Phosphorsaeureloesungen | ChEBI | Phosphorsaeure | ChEBI | Phosphoric acid | Kegg | Orthophosphate | Generator | Concise etchant | MeSH | Condact | MeSH | K-Etchant | MeSH | Uni-etch | MeSH | Phosphate | ChEBI | Diphosphate tetrasodium | HMDB | Marphos | HMDB | NFB | HMDB | ortho- Phosphoric acid | HMDB | Phosphoric acid (acd/name 4.0) | HMDB | Sodium pyrophosphate | HMDB | Sodium pyrophosphate decahydrate | HMDB | Sodium pyrophosphate decahydrate biochemica | HMDB | Sonac | HMDB | Tetra-sodium pyrophosphate | HMDB | Tetrasodium pyrophosphate 10-hydrate | HMDB | Tetrasodium pyrophosphate decahydrate | HMDB | White phosphoric acid | HMDB | Hydrogen phosphoric acid | Generator | Dihydrogen phosphate | HMDB | Hydrogen phosphate | HMDB |
|
---|
Chemical Formula | H3O4P |
---|
Average Molecular Weight | 97.9952 |
---|
Monoisotopic Molecular Weight | 97.976895096 |
---|
IUPAC Name | phosphoric acid |
---|
Traditional Name | phosphoric acid |
---|
CAS Registry Number | 14265-44-2 |
---|
SMILES | OP(O)(O)=O |
---|
InChI Identifier | InChI=1S/H3O4P/c1-5(2,3)4/h(H3,1,2,3,4) |
---|
InChI Key | NBIIXXVUZAFLBC-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of inorganic compounds known as non-metal phosphates. These are inorganic non-metallic compounds containing a phosphate as its largest oxoanion. |
---|
Kingdom | Inorganic compounds |
---|
Super Class | Homogeneous non-metal compounds |
---|
Class | Non-metal oxoanionic compounds |
---|
Sub Class | Non-metal phosphates |
---|
Direct Parent | Non-metal phosphates |
---|
Alternative Parents | |
---|
Substituents | - Non-metal phosphate
- Inorganic oxide
|
---|
Molecular Framework | Not Available |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | Not Available |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | |
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Phosphate,1TMS,isomer #1 | C[Si](C)(C)OP(=O)(O)O | 1173.7 | Semi standard non polar | 33892256 | Phosphate,1TMS,isomer #1 | C[Si](C)(C)OP(=O)(O)O | 1068.7 | Standard non polar | 33892256 | Phosphate,1TMS,isomer #1 | C[Si](C)(C)OP(=O)(O)O | 1578.2 | Standard polar | 33892256 | Phosphate,2TMS,isomer #1 | C[Si](C)(C)OP(=O)(O)O[Si](C)(C)C | 1209.0 | Semi standard non polar | 33892256 | Phosphate,2TMS,isomer #1 | C[Si](C)(C)OP(=O)(O)O[Si](C)(C)C | 1179.7 | Standard non polar | 33892256 | Phosphate,2TMS,isomer #1 | C[Si](C)(C)OP(=O)(O)O[Si](C)(C)C | 1343.5 | Standard polar | 33892256 | Phosphate,3TMS,isomer #1 | C[Si](C)(C)OP(=O)(O[Si](C)(C)C)O[Si](C)(C)C | 1254.1 | Semi standard non polar | 33892256 | Phosphate,3TMS,isomer #1 | C[Si](C)(C)OP(=O)(O[Si](C)(C)C)O[Si](C)(C)C | 1301.5 | Standard non polar | 33892256 | Phosphate,3TMS,isomer #1 | C[Si](C)(C)OP(=O)(O[Si](C)(C)C)O[Si](C)(C)C | 1239.3 | Standard polar | 33892256 | Phosphate,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OP(=O)(O)O | 1440.0 | Semi standard non polar | 33892256 | Phosphate,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OP(=O)(O)O | 1312.0 | Standard non polar | 33892256 | Phosphate,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OP(=O)(O)O | 1755.2 | Standard polar | 33892256 | Phosphate,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OP(=O)(O)O[Si](C)(C)C(C)(C)C | 1664.0 | Semi standard non polar | 33892256 | Phosphate,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OP(=O)(O)O[Si](C)(C)C(C)(C)C | 1605.0 | Standard non polar | 33892256 | Phosphate,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OP(=O)(O)O[Si](C)(C)C(C)(C)C | 1630.9 | Standard polar | 33892256 | Phosphate,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OP(=O)(O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 1885.5 | Semi standard non polar | 33892256 | Phosphate,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OP(=O)(O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 1908.7 | Standard non polar | 33892256 | Phosphate,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OP(=O)(O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 1634.3 | Standard polar | 33892256 |
|
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental GC-MS | GC-MS Spectrum - Hydrogen phosphate GC-MS (3 TMS) | splash10-0002-0794000000-6c866e626b9356994d46 | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Hydrogen phosphate EI-B (Non-derivatized) | splash10-0002-0394000000-3a469377821d88bd699f | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Hydrogen phosphate GC-MS (Non-derivatized) | splash10-0002-0794000000-6c866e626b9356994d46 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Hydrogen phosphate GC-EI-TOF (Non-derivatized) | splash10-000t-0972000000-2ddd7182426dbace5342 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Hydrogen phosphate GC-MS (Non-derivatized) - 70eV, Positive | splash10-0002-9000000000-1805c2208b5ff15a75b1 | 2016-09-22 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Hydrogen phosphate GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Phosphate Quattro_QQQ 10V, N/A-QTOF (Annotated) | splash10-000t-9000000000-0e85f764ac98e8949759 | 2012-07-25 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Phosphate Quattro_QQQ 25V, N/A-QTOF (Annotated) | splash10-001i-9000000000-869a362083996a0cec77 | 2012-07-25 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Phosphate Quattro_QQQ 40V, N/A-QTOF (Annotated) | splash10-03di-9000000000-801101cccfd6c25271d4 | 2012-07-25 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Phosphate LC-ESI-QTOF 10V, positive-QTOF | splash10-0002-9000000000-6f386712e664a4b37a0f | 2020-07-21 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Phosphate LC-ESI-QTOF 20V, positive-QTOF | splash10-0002-9000000000-94c04c712e24776fb333 | 2020-07-21 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Phosphate LC-ESI-QTOF 40V, positive-QTOF | splash10-0002-9000000000-9cc1283f5af78eb26124 | 2020-07-21 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Phosphate LC-ESI-QFT , negative-QTOF | splash10-0002-9000000000-c1da993c0996e8d60830 | 2020-07-21 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Phosphate LC-ESI-QTOF 35V, negative-QTOF | splash10-002b-9000000000-ccb36e7b3439fcc25313 | 2020-07-21 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Phosphate LC-ESI-QTOF 10V, negative-QTOF | splash10-004i-9000000000-e618cbd5a94aa5860a29 | 2020-07-21 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Phosphate LC-ESI-QTOF 20V, negative-QTOF | splash10-004i-9000000000-b7f0efd9272b1a27eac4 | 2020-07-21 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Phosphate LC-ESI-QTOF 40V, negative-QTOF | splash10-004i-9000000000-8cadeed88c84e8c2b6c2 | 2020-07-21 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Phosphate n/a 6V, negative-QTOF | splash10-014i-9000000000-093cd2a2a662118d8432 | 2020-07-21 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Phosphate n/a 6V, negative-QTOF | splash10-004i-9000000000-46d4cee1b5ac630ba9b8 | 2020-07-21 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Phosphate QqQ 1V, negative-QTOF | splash10-0006-0090000000-40333890e636692e7970 | 2020-07-22 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Phosphate QqQ 2V, negative-QTOF | splash10-0006-0190000000-52fa21c93ab4c97f8df2 | 2020-07-22 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Phosphate QqQ 3V, negative-QTOF | splash10-0006-0490000000-32e316211facaa3d3bb2 | 2020-07-22 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Phosphate QqQ 4V, negative-QTOF | splash10-0005-0960000000-bd7aaa47a8ffd82012d3 | 2020-07-22 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Phosphate QqQ 5V, negative-QTOF | splash10-0002-0920000000-463d7b1bf72bcc10126f | 2020-07-22 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Phosphate QqQ 6V, negative-QTOF | splash10-0002-0910000000-3c9c666ac95b68e43224 | 2020-07-22 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Phosphate 10V, Positive-QTOF | splash10-0002-9000000000-12a5e23d24cd494e99c1 | 2016-09-14 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Phosphate 20V, Positive-QTOF | splash10-0002-9000000000-91e06ca38117aabdb14c | 2016-09-14 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Phosphate 40V, Positive-QTOF | splash10-000t-9000000000-19b1c041aa5e2adcc3e6 | 2016-09-14 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Phosphate 10V, Negative-QTOF | splash10-0002-9000000000-e56eecd6724dfbf74160 | 2016-09-14 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Phosphate 20V, Negative-QTOF | splash10-004i-9000000000-0a46ba32971030356ac5 | 2016-09-14 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Phosphate 40V, Negative-QTOF | splash10-004i-9000000000-3a53d27e23b39429d092 | 2016-09-14 | Wishart Lab | View Spectrum |
IR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M-H]-) | 2023-02-03 | FELIX lab | View Spectrum | Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M+H]+) | 2023-02-03 | FELIX lab | View Spectrum | Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M+Na]+) | 2023-02-03 | FELIX lab | View Spectrum |
|
---|
Biological Properties |
---|
Cellular Locations | - Cytoplasm
- Extracellular
- Mitochondria
- Nucleus
- Lysosome
- Endoplasmic reticulum
- Golgi apparatus
- Peroxisome
|
---|
Biospecimen Locations | - Blood
- Feces
- Saliva
- Sweat
- Urine
|
---|
Tissue Locations | - Kidney
- Liver
- Placenta
- Prostate
|
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Detected and Quantified | 379.1 +/- 31.6 uM | Adult (>18 years old) | Male | Normal | | details | Blood | Detected and Quantified | 820.4 uM | Adult (>18 years old) | Both | Normal | | details | Blood | Detected and Quantified | 1400-2200 uM | Not Specified | Not Specified | Normal | | details | Blood | Detected and Quantified | 589.65-1105.60 uM | Newborn (0 - <14 days old) | Both | Normal | | details | Blood | Detected and Quantified | 505.42-884.45 uM | Infant (15 days - <1 year old) | Both | Normal | | details | Blood | Detected and Quantified | 452.77-716.01 uM | Children (1 - <5 years old) | Both | Normal | | details | Blood | Detected and Quantified | 431.71-621.24 uM | Children (5 - <13 years old) | Both | Normal | | details | Blood | Detected and Quantified | 336.94-579.12 uM | Adolescent (13 - <16 years old) | Female | Normal | | details | Blood | Detected and Quantified | 305.36-526.47 uM | Adolescent (16 - <19 years old) | Both | Normal | | details | Blood | Detected and Quantified | 368.53-652.83 uM | Adolescent (13 - <16 years old) | Male | Normal | | details | Blood | Detected and Quantified | 1100 +/- 190 uM | Adult (>18 years old) | Both | Normal | | details | Blood | Detected and Quantified | 1200-1960 uM | Infant (0-1 year old) | Not Specified | Normal | | details | Blood | Detected and Quantified | 400.120-684.417 uM | Children (1-13 years old) | Not Specified | Normal | | details | Blood | Detected and Quantified | 1100.0 (810.0-1450.0) uM | Adult (>18 years old) | Both | Normal | | details | Blood | Detected and Quantified | 1200-2000 uM | Infant (0-1 year old) | Not Specified | Normal | | details | Blood | Detected and Quantified | 1000-2200 uM | Children (1-13 years old) | Not Specified | Normal | | details | Feces | Detected but not Quantified | Not Quantified | Not Specified | Not Specified | Normal | | details | Feces | Detected but not Quantified | Not Quantified | Infant (0-1 year old) | Both | Normal | | details | Feces | Detected but not Quantified | Not Quantified | Infant (0-1 year old) | Not Specified | Normal | | details | Feces | Detected but not Quantified | Not Quantified | Infant (0-1 year old) | Not Specified | Normal | | details | Feces | Detected but not Quantified | Not Quantified | Infant (0-1 year old) | Not Available | Normal | | details | Feces | Detected but not Quantified | Not Quantified | Not Specified | Not Specified | Normal | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Saliva | Detected and Quantified | 27850 +/- 36040 uM | Adult (>18 years old) | Both | Normal | | details | Saliva | Detected and Quantified | 28550 +/- 33790 uM | Adult (>18 years old) | Both | Normal | | details | Saliva | Detected and Quantified | 21450 +/- 21020 uM | Adult (>18 years old) | Both | Normal | | details | Saliva | Detected and Quantified | 17620 +/- 13800 uM | Adult (>18 years old) | Both | Normal | | details | Saliva | Detected and Quantified | 21630 +/- 15830 uM | Adult (>18 years old) | Both | Normal | | details | Saliva | Detected and Quantified | 24100 +/- 16390 uM | Adult (>18 years old) | Both | Normal | | details | Saliva | Detected and Quantified | 22690 +/- 19270 uM | Adult (>18 years old) | Both | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected and Quantified | 2787.81 +/- 1528.51 uM | Adult (>18 years old) | Both | Normal | | details | Sweat | Detected but not Quantified | Not Quantified | Adult | Both | Normal | | details | Urine | Detected and Quantified | 784 (425-1170) umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | Urine | Detected and Quantified | 1000-4900 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | Urine | Detected and Quantified | 1364.27 +/- 915.27 umol/mmol creatinine | Infant (0-1 year old) | Both | Normal | | details | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details |
|
---|
Abnormal Concentrations |
---|
| |
Blood | Detected and Quantified | 450 +/- 30 uM | Adult (>18 years old) | Not Specified | Hypophosphatemia | | details | Blood | Detected and Quantified | 290 +/- 50 uM | Adult (>18 years old) | Not Specified | Hypophosphatemia | | details | Blood | Detected and Quantified | 2800 uM | Infant (0-1 year old) | Female | Pyroglutamic aciduria | | details | Blood | Detected and Quantified | 653.0 +/- 126.0 uM | Adult (>18 years old) | Both | Hemodialysis | | details | Blood | Detected and Quantified | 2700-4700 uM | Infant (0-1 year old) | Both | Hypoparathyroidism-retardation-dysmorphism syndrome | | details | Blood | Detected and Quantified | 1300 +/- 170 uM | Adult (>18 years old) | Both | Hypophosphatasia, infantile | | details | Blood | Detected and Quantified | 126.354 uM | Adult (>18 years old) | Female | Fanconi syndrome | | details | Blood | Detected and Quantified | 315.885 uM | Children (1-13 years old) | Female | Hyperphosphatasia | | details | Blood | Detected and Quantified | 270 (0-540) uM | Adult (>18 years old) | Not Specified | Hypophosphatemia | | details | Blood | Detected and Quantified | 610 +/- 130 uM | Adult (>18 years old) | Not Specified | Hypophosphatemia | | details | Blood | Detected and Quantified | 1700-2000 uM | Infant (0-1 year old) | Not Specified | Oculocerebrorenal Syndrome of Lowe | | details | Blood | Detected and Quantified | 900-2000 uM | Children (1-13 years old) | Not Specified | Oculocerebrorenal Syndrome of Lowe | | details | Blood | Detected and Quantified | 800-1400 uM | Adolescent (13-18 years old) | Not Specified | Oculocerebrorenal Syndrome of Lowe | | details | Blood | Detected and Quantified | 1000-1300 uM | Adult (>18 years old) | Not Specified | Oculocerebrorenal Syndrome of Lowe | | details | Blood | Detected and Quantified | 231.649 uM | Adult (>18 years old) | Male | Bartter Syndrome, Type 4A, Neonatal, with Sensorineural Deafness | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Colorectal cancer | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Colorectal cancer | | details | Feces | Detected but not Quantified | Not Quantified | Not Specified | Not Specified | Cryptosporidium infection | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Colorectal Cancer | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Supragingival Plaque | | details | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Bladder cancer | | details |
|
---|
Associated Disorders and Diseases |
---|
Disease References | Hemodialysis |
---|
- Oikawa O, Higuchi T, Yamazaki T, Yamamoto C, Fukuda N, Matsumoto K: Evaluation of serum fetuin-A relationships with biochemical parameters in patients on hemodialysis. Clin Exp Nephrol. 2007 Dec;11(4):304-8. Epub 2007 Dec 21. [PubMed:18085392 ]
| Hypophosphatemia |
---|
- Amanzadeh J, Reilly RF Jr: Hypophosphatemia: an evidence-based approach to its clinical consequences and management. Nat Clin Pract Nephrol. 2006 Mar;2(3):136-48. [PubMed:16932412 ]
| Bartter Syndrome, Type 4A, Neonatal, with Sensorineural Deafness |
---|
- Heilberg IP, Totoli C, Calado JT: Adult presentation of Bartter syndrome type IV with erythrocytosis. Einstein (Sao Paulo). 2015 Oct-Dec;13(4):604-6. doi: 10.1590/S1679-45082015RC3013. Epub 2015 Oct 30. [PubMed:26537508 ]
| Fanconi syndrome |
---|
- Cheng HM, Jap TS, Ho LT: Fanconi syndrome: report of a case. J Formos Med Assoc. 1990 Dec;89(12):1115-7. [PubMed:1982686 ]
| Hyperphosphatasia |
---|
- Saki F, Karamizadeh Z, Nasirabadi S, Mumm S, McAlister WH, Whyte MP: Juvenile paget's disease in an Iranian kindred with vitamin D deficiency and novel homozygous TNFRSF11B mutation. J Bone Miner Res. 2013 Jun;28(6):1501-8. doi: 10.1002/jbmr.1868. [PubMed:23322328 ]
| Hypoparathyroidism-retardation-dysmorphism syndrome |
---|
- Sanjad SA, Sakati NA, Abu-Osba YK, Kaddoura R, Milner RD: A new syndrome of congenital hypoparathyroidism, severe growth failure, and dysmorphic features. Arch Dis Child. 1991 Feb;66(2):193-6. [PubMed:2001103 ]
| Hypophosphatasia |
---|
- Chodirker BN, Evans JA, Seargeant LE, Cheang MS, Greenberg CR: Hyperphosphatemia in infantile hypophosphatasia: implications for carrier diagnosis and screening. Am J Hum Genet. 1990 Feb;46(2):280-5. [PubMed:2301398 ]
| Oculocerebrorenal syndrome |
---|
- Charnas LR, Bernardini I, Rader D, Hoeg JM, Gahl WA: Clinical and laboratory findings in the oculocerebrorenal syndrome of Lowe, with special reference to growth and renal function. N Engl J Med. 1991 May 9;324(19):1318-25. doi: 10.1056/NEJM199105093241904. [PubMed:2017228 ]
| Colorectal cancer |
---|
- Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016. [PubMed:27275383 ]
- Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016. [PubMed:27015276 ]
- Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18. [PubMed:25037050 ]
| Supragingival Plaque |
---|
- Liebsch C, Pitchika V, Pink C, Samietz S, Kastenmuller G, Artati A, Suhre K, Adamski J, Nauck M, Volzke H, Friedrich N, Kocher T, Holtfreter B, Pietzner M: The Saliva Metabolome in Association to Oral Health Status. J Dent Res. 2019 Jun;98(6):642-651. doi: 10.1177/0022034519842853. Epub 2019 Apr 26. [PubMed:31026179 ]
|
|
---|
Associated OMIM IDs | - 602522 (Bartter Syndrome, Type 4A, Neonatal, with Sensorineural Deafness)
- 239000 (Hyperphosphatasia)
- 241410 (Hypoparathyroidism-retardation-dysmorphism syndrome)
- 241500 (Hypophosphatasia)
- 309000 (Oculocerebrorenal syndrome)
- 114500 (Colorectal cancer)
|
---|
External Links |
---|
DrugBank ID | DB09394 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | FDB013380 |
---|
KNApSAcK ID | C00007408 |
---|
Chemspider ID | 979 |
---|
KEGG Compound ID | C00009 |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Phosphoric_Acid |
---|
METLIN ID | Not Available |
---|
PubChem Compound | 1004 |
---|
PDB ID | Not Available |
---|
ChEBI ID | 26078 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | MDB00013437 |
---|
Good Scents ID | rw1033561 |
---|
References |
---|
Synthesis Reference | Cremer, Josef; Hartmann, Fridolin; Rodis, Franz; Hinz, Arnulf. Preparation of alkali or alkaline earth phosphates with simultaneous recovery of volatile mineral acids. Ger. (1966), 2 pp. CODEN: GWXXAW DE 1227435 19661027 CAN 66:12584 AN 1967:12584 |
---|
Material Safety Data Sheet (MSDS) | Download (PDF) |
---|
General References | - Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762. [PubMed:19212411 ]
- Esteve-Romero J, Capella-Peiro ME, Monferrer-Pons L, Gil-Agusti M: Micellar liquid chromatography in clinical chemistry: application to the monitorization of B6 vitamins. Clin Chim Acta. 2004 Oct;348(1-2):69-77. [PubMed:15369738 ]
- Hem SL, Hogenesch H: Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev Vaccines. 2007 Oct;6(5):685-98. [PubMed:17931150 ]
- Srivastava T, Alon US: Pathophysiology of hypercalciuria in children. Pediatr Nephrol. 2007 Oct;22(10):1659-73. Epub 2007 Apr 27. [PubMed:17464515 ]
- Pietak AM, Reid JW, Stott MJ, Sayer M: Silicon substitution in the calcium phosphate bioceramics. Biomaterials. 2007 Oct;28(28):4023-32. Epub 2007 May 17. [PubMed:17544500 ]
- Keul P, Sattler K, Levkau B: HDL and its sphingosine-1-phosphate content in cardioprotection. Heart Fail Rev. 2007 Dec;12(3-4):301-6. [PubMed:17554629 ]
- Isales CM, McDonald JM: Future developments in therapy. Ann N Y Acad Sci. 2007 Nov;1117:258-63. Epub 2007 Jun 21. [PubMed:17584984 ]
- Pumo V, Sciacca D, Malaguarnera M: Tumor lysis syndrome in elderly. Crit Rev Oncol Hematol. 2007 Oct;64(1):31-42. Epub 2007 Jul 19. [PubMed:17658268 ]
- Breitkreutz D, Braiman-Wiksman L, Daum N, Denning MF, Tennenbaum T: Protein kinase C family: on the crossroads of cell signaling in skin and tumor epithelium. J Cancer Res Clin Oncol. 2007 Nov;133(11):793-808. Epub 2007 Jul 28. [PubMed:17661083 ]
- Tiwari S, Riazi S, Ecelbarger CA: Insulin's impact on renal sodium transport and blood pressure in health, obesity, and diabetes. Am J Physiol Renal Physiol. 2007 Oct;293(4):F974-84. Epub 2007 Aug 8. [PubMed:17686957 ]
- Argraves KM, Argraves WS: HDL serves as a S1P signaling platform mediating a multitude of cardiovascular effects. J Lipid Res. 2007 Nov;48(11):2325-33. Epub 2007 Aug 13. [PubMed:17698855 ]
- Brown BA, Kantesaria PP, McDevitt LM: Fingolimod: a novel immunosuppressant for multiple sclerosis. Ann Pharmacother. 2007 Oct;41(10):1660-8. Epub 2007 Sep 4. [PubMed:17785617 ]
- Toussaint ND, Kerr PG: Vascular calcification and arterial stiffness in chronic kidney disease: implications and management. Nephrology (Carlton). 2007 Oct;12(5):500-9. [PubMed:17803475 ]
- Munteanu A, Zingg JM: Cellular, molecular and clinical aspects of vitamin E on atherosclerosis prevention. Mol Aspects Med. 2007 Oct-Dec;28(5-6):538-90. Epub 2007 Aug 3. [PubMed:17825403 ]
- Nauseef WM: How human neutrophils kill and degrade microbes: an integrated view. Immunol Rev. 2007 Oct;219:88-102. [PubMed:17850484 ]
- Allen LA, McCaffrey RL: To activate or not to activate: distinct strategies used by Helicobacter pylori and Francisella tularensis to modulate the NADPH oxidase and survive in human neutrophils. Immunol Rev. 2007 Oct;219:103-17. [PubMed:17850485 ]
- Giavazzi R, Bani MR, Taraboletti G: Tumor-host interaction in the optimization of paclitaxel-based combination therapies with vascular targeting compounds. Cancer Metastasis Rev. 2007 Dec;26(3-4):481-8. [PubMed:17896168 ]
- Tonelli M, Wiebe N, Culleton B, Lee H, Klarenbach S, Shrive F, Manns B: Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant. 2007 Oct;22(10):2856-66. [PubMed:17906326 ]
- Miyamoto K, Tatsumi S, Ito M, Segawa H: [New aspect of renal phosphate reabsorption and phosphate metabolism]. Clin Calcium. 2007 Oct;17(10):1485-92. [PubMed:17906398 ]
- Michigami T: [Vitamin D metabolism and action]. Clin Calcium. 2007 Oct;17(10):1493-8. [PubMed:17906399 ]
- Hoshi K: [Mechanisms of bone calcification]. Clin Calcium. 2007 Oct;17(10):1499-507. [PubMed:17906400 ]
- Takeuchi Y: [Pathophysiology in rickets/osteomalacia]. Clin Calcium. 2007 Oct;17(10):1508-13. [PubMed:17906401 ]
- Ito N, Fukumoto S: [FGF23-related hypophosphatemic rickets/osteomalacia]. Clin Calcium. 2007 Oct;17(10):1514-20. [PubMed:17906402 ]
- Sekine T: [Rickets/osteomalacia due to tubular dysfunction]. Clin Calcium. 2007 Oct;17(10):1529-33. [PubMed:17906404 ]
- Sato K: [Drug-induced osteomalacia]. Clin Calcium. 2007 Oct;17(10):1536-42. [PubMed:17906405 ]
- Hasegawa Y, Miyamoto J: [Hypophosphatemic rickets/osteomalacia. - Mainly on patients with PHEX mutations -]. Clin Calcium. 2007 Oct;17(10):1592-9. [PubMed:17906414 ]
- Bragadeesh TK, Mathur G, Clark AL, Cleland JG: Novel cardiac myosin activators for acute heart failure. Expert Opin Investig Drugs. 2007 Oct;16(10):1541-8. [PubMed:17922619 ]
- Worthington HV, Clarkson JE, Eden OB: Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD000978. [PubMed:17943748 ]
- Nixon GF, Mathieson FA, Hunter I: The potential roles of sphingolipids in vascular smooth-muscle function. Biochem Soc Trans. 2007 Nov;35(Pt 5):908-9. [PubMed:17956243 ]
- Johnson D, Shepherd RM, Gill D, Gorman T, Smith DM, Dunne MJ: Glucokinase activators: molecular tools for studying the physiology of insulin-secreting cells. Biochem Soc Trans. 2007 Nov;35(Pt 5):1208-10. [PubMed:17956314 ]
- Ku NO, Strnad P, Zhong BH, Tao GZ, Omary MB: Keratins let liver live: Mutations predispose to liver disease and crosslinking generates Mallory-Denk bodies. Hepatology. 2007 Nov;46(5):1639-49. [PubMed:17969036 ]
- Beutler E, Duparc S: Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Am J Trop Med Hyg. 2007 Oct;77(4):779-89. [PubMed:17978087 ]
- Van Brocklyn JR: Sphingolipid signaling pathways as potential therapeutic targets in gliomas. Mini Rev Med Chem. 2007 Oct;7(10):984-90. [PubMed:17979800 ]
- Raben DM, Tu-Sekine B: Nuclear diacylglycerol kinases: regulation and roles. Front Biosci. 2008 Jan 1;13:590-7. [PubMed:17981572 ]
- Dubin A, Estenssoro E: Mechanisms of tissue hypercarbia in sepsis. Front Biosci. 2008 Jan 1;13:1340-51. [PubMed:17981634 ]
- Deng ZL, Sharff KA, Tang N, Song WX, Luo J, Luo X, Chen J, Bennett E, Reid R, Manning D, Xue A, Montag AG, Luu HH, Haydon RC, He TC: Regulation of osteogenic differentiation during skeletal development. Front Biosci. 2008 Jan 1;13:2001-21. [PubMed:17981687 ]
- Liu X, Elojeimy S, Turner LS, Mahdy AE, Zeidan YH, Bielawska A, Bielawski J, Dong JY, El-Zawahry AM, Guo GW, Hannun YA, Holman DH, Rubinchik S, Szulc Z, Keane TE, Tavassoli M, Norris JS: Acid ceramidase inhibition: a novel target for cancer therapy. Front Biosci. 2008 Jan 1;13:2293-8. [PubMed:17981711 ]
- Su N, Du X, Chen L: FGF signaling: its role in bone development and human skeleton diseases. Front Biosci. 2008 Jan 1;13:2842-65. [PubMed:17981758 ]
- Trimble JL, Kockler DR: Statin treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Ann Pharmacother. 2007 Dec;41(12):2019-23. Epub 2007 Nov 6. [PubMed:17986515 ]
- Zeitels SM, Burns JA: Office-based laryngeal laser surgery with the 532-nm pulsed-potassium-titanyl-phosphate laser. Curr Opin Otolaryngol Head Neck Surg. 2007 Dec;15(6):394-400. [PubMed:17986877 ]
- Pebay A, Bonder CS, Pitson SM: Stem cell regulation by lysophospholipids. Prostaglandins Other Lipid Mediat. 2007 Nov;84(3-4):83-97. Epub 2007 Sep 5. [PubMed:17991611 ]
- Komarova YA, Mehta D, Malik AB: Dual regulation of endothelial junctional permeability. Sci STKE. 2007 Nov 13;2007(412):re8. [PubMed:18000237 ]
- Burger EL, Patel V: Calcium phosphates as bone graft extenders. Orthopedics. 2007 Nov;30(11):939-42. [PubMed:18019987 ]
- Qin C, D'Souza R, Feng JQ: Dentin matrix protein 1 (DMP1): new and important roles for biomineralization and phosphate homeostasis. J Dent Res. 2007 Dec;86(12):1134-41. [PubMed:18037646 ]
- Andress DL: Bone and mineral guidelines for patients with chronic kidney disease: a call for revision. Clin J Am Soc Nephrol. 2008 Jan;3(1):179-83. Epub 2007 Dec 5. [PubMed:18057310 ]
- Fukumoto S: [Parathyroid and bone. Calcimimetics and bone metabolism]. Clin Calcium. 2007 Dec;17(12):1865-9. [PubMed:18057662 ]
- Fei X, Qin Z, Liang Z: Contribution of CDP/Cux, a transcription factor, to cell cycle progression. Acta Biochim Biophys Sin (Shanghai). 2007 Dec;39(12):923-30. [PubMed:18064384 ]
- Bonomini F, Tengattini S, Fabiano A, Bianchi R, Rezzani R: Atherosclerosis and oxidative stress. Histol Histopathol. 2008 Mar;23(3):381-90. doi: 10.14670/HH-23.381. [PubMed:18072094 ]
- Orcel P, Chapurlat R: [Fibrous dysplasia of bone]. Rev Prat. 2007 Oct 31;57(16):1749-55. [PubMed:18092715 ]
- Damron TA: Use of 3D beta-tricalcium phosphate (Vitoss) scaffolds in repairing bone defects. Nanomedicine (Lond). 2007 Dec;2(6):763-75. [PubMed:18095844 ]
- Hertz A, Bruce IJ: Inorganic materials for bone repair or replacement applications. Nanomedicine (Lond). 2007 Dec;2(6):899-918. [PubMed:18095853 ]
- Cappellini MD, Fiorelli G: Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008 Jan 5;371(9606):64-74. doi: 10.1016/S0140-6736(08)60073-2. [PubMed:18177777 ]
- Faiman C, Moorhouse JA: Diurnal variation in the levels of glucose and related substances in healthy and diabetic subjects during starvation. Clin Sci. 1967 Feb;32(1):111-26. [PubMed:5336272 ]
- Virkki LV, Biber J, Murer H, Forster IC: Phosphate transporters: a tale of two solute carrier families. Am J Physiol Renal Physiol. 2007 Sep;293(3):F643-54. Epub 2007 Jun 20. [PubMed:17581921 ]
- Pohlmeier R, Vienken J: Phosphate removal and hemodialysis conditions. Kidney Int Suppl. 2001 Feb;78:S190-4. [PubMed:11169009 ]
- Gallar P, Ortega O, Gutierrez M, Munoz M, Hilara L, Oliet A, Rodriguez I, Gimenez E, Vigil A: [Influencing factors in the control of phosphorus in peritoneal dialysis. Therapeutic options]. Nefrologia. 2000 Jul-Aug;20(4):355-61. [PubMed:11039261 ]
- Cruz DN, Perazella MA: Biochemical aberrations in a dialysis patient following parathyroidectomy. Am J Kidney Dis. 1997 May;29(5):759-62. [PubMed:9159312 ]
- Nemere I: The ins and outs of phosphate homeostasis. Kidney Int. 2007 Jul;72(2):140-2. [PubMed:17625581 ]
- Elshenawy S, Pinney SE, Stuart T, Doulias PT, Zura G, Parry S, Elovitz MA, Bennett MJ, Bansal A, Strauss JF 3rd, Ischiropoulos H, Simmons RA: The Metabolomic Signature of the Placenta in Spontaneous Preterm Birth. Int J Mol Sci. 2020 Feb 4;21(3). pii: ijms21031043. doi: 10.3390/ijms21031043. [PubMed:32033212 ]
|
---|